Recursion Pharmaceuticals, Inc. proof-of-concept data, from the phase 2 SYCAMORE study using REC-994 for the treatment of patients with Cerebral Cavernous Malformation, expected in the 2nd half of ...
Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback